Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00975975 · OUTCOME

Grade 3-4 Acute GVHD Rate

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer · Source last updated 2016-02-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Transplant (Day 0) up to 1 year

What was measured

The percent of patients where a patient experienced a Grade 3 or 4 acute GVHD

Analysis population: All patients enrolled and received treatment

Groups in this outcome

Overall

Patients administered 40 mg of basiliximab as a single intravenous dose on day +7, +8, or +9 following infusion of allogeneic peripheral blood hematopoietic cells

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Overall17

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Overall29.4Not reported10.356.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        10.3
        upper Limit
        56.0
        value
        29.4
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
description
The percent of patients where a patient experienced a Grade 3 or 4 acute GVHD
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients administered 40 mg of basiliximab as a single intravenous dose on day +7, +8, or +9 following infusion of allogeneic peripheral blood hematopoietic cells
    id
    OG000
    title
    Overall
param Type
NUMBER
population Description
All patients enrolled and received treatment
reporting Status
POSTED
time Frame
Transplant (Day 0) up to 1 year
title
Grade 3-4 Acute GVHD Rate
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice